Treatment Experience Using a Micro‐Induction Buprenorphine Protocol for Chronic Pain in Pediatric Sickle Cell Disease
Inpatient micro-induction to BUP from FOA in adolescent SCD patients with CP is feasible with minimal signs of opioid withdrawal. This study suggests decreased acute care utilization with BUP.
Authors
- Beatrice E. Gee (ORCID: https://orcid.org/0000-0003-0233-0321)
- Ifeyinwa Osunkwo (ORCID: https://orcid.org/0000-0001-9368-2247)
- Ashwin Patel (ORCID: https://orcid.org/0000-0003-0075-3304)
- Carlton Dampier (ORCID: https://orcid.org/0000-0002-7738-2620)
- Gerhard W. Kalmus
- Elna Saah (ORCID: https://orcid.org/0009-0000-8694-3496)
- Tamara New (ORCID: https://orcid.org/0009-0000-2671-101X)
Institutions
- Johns Hopkins University (US)
- Emory University (US)
- Johns Hopkins All Children's Hospital (US)
- Novo Nordisk (Switzerland) (CH)
- Aflac (United States) (US)
- Children's Healthcare of Atlanta (US)
Publication Details
- Journal
- Pediatric Blood & Cancer
- Published
- 2025-05-24
- DOI
- https://doi.org/10.1002/pbc.31731
- Citations
- 1
- Primary Topic
- Hemoglobinopathies and Related Disorders
- Type
- article
- Field-Weighted Citation Impact
- 1.63